Developing Meaningful Therapeutics in the Fight Against Cancer
Aptevo’s platforms are purposefully engineered to control immune activation with precision — supporting clinical proof-of-concept, safer therapeutic design, pipeline scalability, and expansion into emerging radiopharmaceutical combinations.
Mipletamig* AML data validate Aptevo’s approach to controlled immune activation, with limited CRS; monotherapy activity in R/R setting and strong remission activity in frontline patients in combination with standard of care (venetoclax + azacitidine).
Niowave collaboration extends Aptevo’s multispecific platform into novel radiopharmaceutical combinations, creating a new path for differentiation, partnering, and value creation.
Niowave collaboration extends Aptevo’s multispecific platform into novel radiopharmaceutical combinations, creating a new path for differentiation, partnering, and value creation.
Aptevo’s unique use and application of the CRIS-7-derived CD3 binding domain is designed to engage T cells while reducing systemic cytokine risk — a key limitation of many immune-engaging therapies.
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage immuno-oncology company focused on developing new therapeutics to meaningfully fight cancer, improve treatment outcomes and transform the lives of cancer patients.
Advancing molecules designed for clinical impact, safety and combinability with existing standards of care and emerging therapies.
Aptevo Pipeline Carousel — Slide Transition
Mipletamig: Advancing Toward a New Standard in Frontline AML
Mipletamig is building momentum toward a potential new standard in frontline AML. With RAINIER Phase 1b completion expected by year-end and planned Phase 2 initiation in 1H27, the program is entering a defining stage backed by strong efficacy, safety and tolerability data.
Trispecific Molecules: Three-in-One Immune Activation for Solid Tumors
Trispecifics are emerging as one of the most exciting frontiers in immuno-oncology, especially in solid tumors. Aptevo's APVO451 brings tumor targeting, T-cell engagement and CD40-mediated immune activation together in one coordinated, tumor-directed molecule — backed by a $1.5 million non-dilutive CARE Fund grant advancing it toward IND submission.
Radiopharmaceutical Therapeutics (RPTs): Precision Targeting Meets the Power of Radioisotopes
RPTs are one of oncology's most compelling new frontiers, with more than $17 billion already invested across RPT assets, licensing, infrastructure and isotope supply. Through its 50/50 collaboration with Niowave, Aptevo is pairing its multispecific targeting platforms with the isotope production and supply capabilities needed to compete in a supply-constrained market.
Aptevo is advancing differentiated immune activation, with clinical proof-of-concept in AML and a pipeline designed to create multiple value drivers across multispecific antibodies and emerging radiopharmaceutical combinations.
